company. In the second study, patients were prospectively enrolled and the costs of genotyping were paid by AssureRx.
At the end of the patient's hospital stay, a Likert scale (1-5, 5 = best) and open-ended questions were given to the patient and clinician. Patients were asked about their expectations of genotyping, how well the results were explained to them, and their overall satisfaction. Clinicians were asked to rate satisfaction with report turnaround time, the usefulness of the report, whether the report influenced treatment decisions, and their overall satisfaction. We included only those surveys that were part of a complete set, that is, both the patient and the treating clinician completed the surveys.
The first study, conducted from March to September 2008, resulted in 37 complete sets of patient and clinician responses. Eightysix patients received genotyping ordered by 3 unique clinicians. The second study, conducted from November 2008 to February 2009, resulted in 38 complete sets of responses. Fifty-one patients received genotyping ordered by 6 unique clinicians. Patients were predominantly female (70%) and had a mean age of 44 years.
Results. Patient satisfaction. For the first study, 14 patients (38%) were aware of genotyping prior to hospitalization, compared to 8 patients (21%) in the second study. Mean overall satisfaction with the first and second reports was 3.4 and 3.8 (1-5 scale, 5 = best), respectively. Mean patient perception of the clinician's explanation of test results was 3.6 and 4.1, respectively.
Clinician satisfaction. Mean overall clinician satisfaction was 3.5 for the first report and 3.7 for the second report. Other results, reported as the first study versus the second study, were 37% (10/27, the denominator representing instances when genotyping results were available by discharge and both patient and clinician completed the survey) versus 50% (n = 17/34) changed medications based on test results, 3.5 versus 4.6 for "ease of use" of the test results, 3.3 versus 3.7 for "influence on decision making, " 3.6 versus 3.9 for "usefulness, " and 3.4 versus 3.7 for "satisfaction with turnaround time. " For turnaround time, results fully available to clinicians by the time of discharge were 57% for the first report and 72% for the second report.
Genotyping is well-received by inpatients with depression and their treating clinicians, and up to 50% of clinicians reported that the genotyping results changed their medication management strategies. Patients and clinicians reported satisfaction higher than the "average" score of 3 on a 5-point Likert scale. The second report (GeneSightRx) was consistently rated higher than the first report (Mayo Medical Laboratories).
